Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended June 20, 2025, including: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and South Korea proposes new AI R&D project.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories Mentioned In This Episode:
- BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties
- Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve
- UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote
- Ireland’s Got Biopharma Talent To Keep Leading The Pack
- Profit-Sharing AI Model Proposed To Boost Korean Drug R&D